Short Interest in Mediwound Ltd (NASDAQ:MDWD) Drops By 16.9%

Share on StockTwits

Mediwound Ltd (NASDAQ:MDWD) saw a significant decline in short interest in the month of November. As of November 29th, there was short interest totalling 114,400 shares, a decline of 16.9% from the November 14th total of 137,700 shares. Based on an average trading volume of 40,500 shares, the short-interest ratio is presently 2.8 days. Approximately 0.7% of the shares of the company are sold short.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oppenheimer & Co. Inc. lifted its position in Mediwound by 11.0% during the third quarter. Oppenheimer & Co. Inc. now owns 48,600 shares of the biopharmaceutical company’s stock valued at $156,000 after purchasing an additional 4,800 shares in the last quarter. California Public Employees Retirement System lifted its position in Mediwound by 5.8% during the third quarter. California Public Employees Retirement System now owns 211,500 shares of the biopharmaceutical company’s stock valued at $670,000 after purchasing an additional 11,600 shares in the last quarter. Sargent Investment Group LLC lifted its position in Mediwound by 114.8% during the second quarter. Sargent Investment Group LLC now owns 29,000 shares of the biopharmaceutical company’s stock valued at $98,000 after purchasing an additional 15,500 shares in the last quarter. Finally, Marshall Wace LLP purchased a new position in Mediwound during the first quarter valued at $93,000. Institutional investors own 26.19% of the company’s stock.

Shares of MDWD remained flat at $$3.00 during trading hours on Thursday. The company had a trading volume of 54,700 shares, compared to its average volume of 138,271. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.65 and a quick ratio of 3.52. Mediwound has a one year low of $2.55 and a one year high of $6.09. The company has a market cap of $82.62 million, a price-to-earnings ratio of -6.12 and a beta of 0.48. The firm has a 50 day moving average price of $2.95 and a two-hundred day moving average price of $3.21.

Mediwound (NASDAQ:MDWD) last released its earnings results on Thursday, November 14th. The biopharmaceutical company reported ($0.01) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.12. The company had revenue of $5.14 million for the quarter, compared to the consensus estimate of $2.67 million. Mediwound had a negative return on equity of 94.57% and a net margin of 69.50%. As a group, analysts forecast that Mediwound will post -0.51 EPS for the current fiscal year.

Several brokerages recently commented on MDWD. Oppenheimer cut their price objective on Mediwound from $15.00 to $7.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Zacks Investment Research raised Mediwound from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a report on Wednesday, November 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $5.50 price objective on shares of Mediwound in a report on Friday, November 15th.

Mediwound Company Profile

MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina.

Recommended Story: Trade Deficit

Receive News & Ratings for Mediwound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediwound and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.